key: cord-0867940-x8oqwccu authors: Ito, Yusuke; Honda, Akira; Kurokawa, Mineo title: COVID-19 mRNA vaccine in patients with lymphoid malignancy or anti-CD20 antibody therapy: a systematic review and meta-analysis date: 2022-03-28 journal: Clin Lymphoma Myeloma Leuk DOI: 10.1016/j.clml.2022.03.012 sha: f50db726cabc005500c3c093a7bba52c3589d023 doc_id: 867940 cord_uid: x8oqwccu BACKGROUND: : The humoral response to vaccination in individuals with lymphoid malignancies or those undergoing anti-CD20 antibody therapy is impaired, but details of the response to mRNA vaccines to protect against COVID-19 remain unclear. This systematic review and meta-analysis aimed to characterize the response to COVID-19 mRNA vaccines in patients with lymphoid malignancies or those undergoing anti-CD20 antibody therapy. MATERIALS AND METHODS: A literature search retrieved 52 relevant articles, and random-effect models were used to analyze humoral and cellular responses. RESULTS: Lymphoid malignancies and anti-CD20 antibody therapy for non-malignancies were significantly associated with lower seropositivity rates (risk ratio [RR] 0.60 [95% confidence interval (CI) 0.53–0.69]; RR 0.45 [95% CI 0.39–0.52], respectively). Some subtypes (chronic lymphocytic leukemia [CLL], treatment-naïve CLL, myeloma, and non-Hodgkin's lymphoma) exhibited impaired humoral response. Anti-CD20 antibody therapy within 6 months of vaccination decreased humoral response; moreover, therapy > 12 months before vaccination still impaired the humoral response. However, anti-CD20 antibody therapy in non-malignant patients did not attenuate T cell responses. CONCLUSION: : These data suggest that patients with lymphoid malignancies or those undergoing anti-CD20 antibody therapy experience an impaired humoral response, but cellular response can be detected independent of anti-CD20 antibody therapy. Studies with long-term follow-up of vaccine effectiveness are warranted (PROSPERO registration number: CRD42021265780). MICRO ABSTRACT: : mRNA vaccines have been widely used for the prevention of coronavirus disease 2019 (COVID-19). This meta-analysis of 52 articles demonstrated that lymphoid malignancies and anti-CD20 antibody therapy impaired humoral response. Individuals with hematological malignancies are highly susceptible to severe coronavirus disease 2019 (COVID-19). 1, 2 The risk for death predominantly among the hospitalized adult population has been reported to be as high as 34%. 3 Patients with chronic lymphocytic leukemia (CLL), 4,5 myeloma, 6,7 or lymphoma 8 are likely to develop serious symptoms due to immunological abnormalities caused by the disease itself and the corresponding immunosuppressive therapies. 9,10 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to angiotensin-converting enzyme 2 receptors expressed on oral mucosa epithelial cells and lung alveolar type II cells through the receptor binding domain in its spike protein. [11] [12] [13] Messenger RNA (mRNA) vaccines targeting the spike protein have been rapidly developed, 14,15 and two, BNT162b2 16 and mRNA-1273, 17 conferred approximately 95% protection against COVID-19 in clinical trials. However, immunocompromised subjects were excluded from these trials; thus, the efficacy of mRNA vaccines in those with hematological malignancies remains under investigation. Lymphoid malignancies and B cell depletion agents, such as anti-CD20 antibody, have been shown to attenuate conventional vaccine effectiveness. 18, 19 6 Anti-CD20 antibody therapy is efficacious against lymphoma, as well as multiple sclerosis and rheumatic diseases, and some guidelines for rheumatic diseases recommend delaying the administration of vaccines for 5 to 6 months after anti-CD20 therapy to maximize humoral response 20,21 ; nevertheless, evidence for mRNA vaccines remains insufficient in this regard. Neutralizing antibodies generated by the humoral response exert immune protection, 22 while the SARS-CoV-2-specific cellular response is also essential for viral elimination and prevention of disease aggravation. 23-25 It remains controversial whether lymphoid malignancies or B cell depletion therapies attenuate cellular responses to the vaccine, and the interaction between T cells and B cells is indispensable for infection control. [26] [27] [28] [29] Two mRNA vaccines have been approved for use against COVID-19, and real-world data regarding the response to these vaccines in various patient types have accumulated rapidly. The present systematic review and meta-analysis investigated humoral and cellular immune responses to COVID-19 mRNA vaccines in patients with lymphoid malignancies and those who underwent treatment with anti-CD20 antibody. This study was registered with PROSPERO (CRD42021265780) and performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. 30 The PubMed and World Health Organization (WHO) COVID-19 database were searched for articles published up to October 2, 2021, without language restriction using the following terms: ("lymphoid malignancy" OR "lymphoid neoplasm" OR lymphoma OR myeloma OR MM OR MGUS OR CLL OR anti-CD20 OR CD20 OR rituximab OR obinutuzumab OR ofatumumab OR ocrelizumab OR veltuzumab OR ocaratuzumab OR ublituximab OR tositumomab OR ibritumomab) AND vaccin* AND (COVID-19 OR SARS-CoV-2). Two authors (YI and AH) independently assessed the titles and abstracts of all articles retrieved in the electronic literature search. Subsequently, the full texts of potentially eligible articles were screened. Studies that lacked sufficient information needed to evaluate outcomes, those that analyzed data only after the first dose of mRNA vaccines, duplicate publications using overlapping patient cohorts, and case series or cohorts with 9 < 10 patients were excluded. Any discrepancies between the authors were resolved through discussion until consensus was reached. A flow diagram of the data extraction process is presented in Figure 1 . The Newcastle-Ottawa scale was used to assess the quality of non-randomized trials. The primary outcome in the present review was the risk ratio (RR) of the seropositive rates of SARS-CoV-2-specific antibody after the second dose of mRNA vaccine. The secondary outcome was the RR of SARS-CoV-2-specific T cell-positive rates after vaccination. Regarding the interval from anti-CD20 antibody therapy to the first vaccine dose, data were extracted from figures whenever possible. The focus was on mRNA vaccines (BNT162b2 and mRNA-1273); however, some articles included adenoviral vaccines: AZD1222 (ChAdOx1 nCov-19) 31 and Ad26.CoV2.S. 32 Data were analyzed using EZR (Easy R) statistical software. 33 For each trial, the vaccine response in patients and controls was calculated using RRs. Data were entered into the EZR software for statistical analysis. An RR < 1 indicated an impaired response 10 in the patient group. The random effect model was used in accordance with the method described by Der Simonian-Laird. 34 Trial results were assessed using the chi-square test of heterogeneity and the I 2 measure of inconsistency. Heterogeneity was considered to be statistically significant at p < 0.10 or an I 2 statistic > 50%. Publication bias was examined using funnel plots coupled with the Egger"s test. Pooled estimates were calculated using the MetaXL add-in for Excel (Microsoft Corporation, Redmond, WA, USA). 35 The literature search of the PubMed and WHO COVID-19 database retrieved 493 articles after removal of duplicates, of which 80 were considered to be relevant through evaluation of titles and abstracts. Among them, 52 studies fulfilled the criteria for the present meta-analysis: 30 investigated lymphoid malignancies 36-65 ; and 22 investigated anti-CD20 antibody therapy for non-malignant diseases, such as multiple sclerosis and rheumatic diseases. 28 articles were excluded with the following reasons: (1) insufficient data of outcomes, [88] [89] [90] [91] [92] [93] [94] [95] [96] (2) duplicate publications from an overlapping cohort, [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] and (3) case series or cohorts with < 10 patients. [107] [108] [109] [110] [111] [112] [113] [114] [115] A flow diagram of the article selection process is shown in Figure 1 , and the characteristics of each study 11 are summarized in Table 1 . Data regarding humoral response in lymphoid malignancies compared with healthy controls were reported in 20 articles 37,39-43,46,47,49-52,54,59-65 that included 2203 patients with CLL, myeloma, non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL). Patients with lymphoid malignancies exhibited significantly lower seropositivity rates than healthy controls (RR 0.60 [95% CI 0.53-0.69]), with high heterogeneity (I 2 = 94%, p < 0.01) ( Fig. 2A) . The funnel plot suggested a publication bias (p < 0.05, Fig. 2B ). Individual subtypes of lymphoid malignancies were analyzed. First, for CLL, a positive humoral response was observed in 52% (95% CI 43%-62%) 42 (Fig. 3D) . Third, for NHL, a positive humoral response was observed in 61% (95% CI 50-71%) (Fig. 3E) . 36 Low-risk patients with CLL, smoldering multiple myeloma (SMM), and indolent NHL are often offered "watchful waiting" until disease progression, and data regarding treatment-naïve patients can be used to estimate the extent to which lymphoid 13 malignancy itself impairs immune function. First, for CLL, positive humoral response was observed in 77% (95% CI 63%-88%) of treatment-naïve patients, 42 Next, the impact of B-cell target therapy on humoral response was analyzed, first focusing on anti-CD20 antibody. Patients treated with anti-CD20 antibody exhibited a lower seropositivity rate than healthy controls (RR 0. The impact of anti-CD20 antibody on immune response, including cellular immunity, was further analyzed by focusing on non-malignant patients treated with anti-CD20 antibody. First, the relationship between humoral response and anti-CD20 antibody was investigated. Data from 16 articles (900 patients) revealed that anti-CD20 antibody treatment significantly decreased seropositivity rates compared with the control group The influence of anti-CD20 antibody therapy on cellular response was investigated. Six studies examined SARS-CoV-2-specific T cell responses using the interferon gamma (IFN-γ) assay, 68, 69, 78, 84, 85, 87 and revealed that 78% of patients treated with anti-CD20 antibody elicited a positive cellular response (95% CI 45%-99%) ( Fig. 7A ) that was comparable with the control group (RR 0.77 [95% CI 0.55-1.08]) 68, 69, 78, 84, 85 (Fig. 7B ). In addition, four studies examined cellular responses using an activation-induced marker (AIM) assay, two of which revealed no significant difference without available quantitative data. 81, 82 The meta-analysis of other two articles exhibited no difference between patients treated with anti-CD20 antibody and controls (AIM-positive CD4 cell, Lymphoid malignancies attenuated the humoral response to COVID-19 mRNA vaccines. Moreover, subgroup analysis further revealed that CLL, NHL, and myeloma patients exhibited decreased seropositivity rates. Patients with lymphoid malignancies are immunocompromised due to the disease itself. 9,10 In particular, treatment-naïve CLL patients exhibited lower seropositivity rates than healthy controls. In CLL patients, the humoral response was also impaired after contracting COVID-19, 116 and the effectiveness of other conventional vaccines was attenuated. 18 These data reflect the substantial immune abnormalities associated with CLL itself. 117, 118 On the other hand, patients with HL and treatment-naïve SMM exhibited high seropositivity rates that were equivalent to healthy controls, suggesting a difference in the influence of disease subtype on the immune system. With regard to the influence of treatment on humoral response, anti-CD20 antibody, anti-CD38 therapy, and BTK inhibitor significantly decreased seropositivity rates. These agents target B cell function, and many studies have demonstrated a correlation 17 between B cell counts in peripheral blood and seropositivity rates. 36,38,40,43,63 These agents have also been reported to decrease the effectiveness of several other conventional vaccines. [119] [120] [121] [122] [123] Regarding anti-CD20 antibody therapy, we analyzed vaccine immunogenicity divided by the interval from the last infusion to the first vaccine dose. An interval of < 6 months and 12 months significantly attenuated seropositivity rates. These results were confirmed in a meta-analysis of non-malignant patients treated with anti-CD20 antibody. B cell reconstitution occurs > 6 months after anti-CD20 antibody therapy, 124, 125 and some guidelines for rheumatic diseases recommend delaying administration of the vaccine for 5 to 6 months after anti-CD20 therapy. 20,21 A recent meta-analysis of influenza vaccine also demonstrated that anti-CD20 antibody treatment within at least the past 6 months abrogated the humoral response, 19 which is consistent with the results of our meta-analysis. Moreover, some articles reported that recovery of the memory B-cell pool after anti-CD20 antibody therapy in the lymphoma population is delayed compared with normal B-cell ontogeny and remains impaired after 12 months. 47,124 Our meta-analysis revealed that anti-CD20 antibody therapy >12 months before vaccination still attenuated the humoral response However, CD8-positive T cells can positively influence recovery 133, 134 ; thus, activation of cellular immunity without humoral response can provide a level of efficacy. This meta-analysis had several limitations. First, we evaluated antibody formation several weeks after vaccination. In addition to immunogenicity, long-term vaccine effectiveness is an important parameter in evaluating vaccine function. Several studies have shown that antibody titers tend to be lower than in healthy controls, even in seropositive patients with lymphoid malignancies; thus, long-term follow-up is further warranted. Second, the heterogeneity in disease status and treatment history in each study will affect the seroresponse to vaccines. For example, MM patients with a complete response (CR) achieved higher antibody levels than non-CR patients, 43 and exposure to > 3 novel anti-myeloma dugs were associated with lower response rates. 46 Therefore, humoral response in each status should be further analyzed individually. Also, anti-CD20 antibody is often used with cytotoxic agents or other immunosuppressive agents as combination therapy, and these agents will affect the humoral response to vaccines. Third, the measurement method for SARS-CoV-2 antibodies and cut-off values of seropositivity differed among the selected studies as summarized in Table 1 . Most studies evaluated antibodies against the receptor binding domain or total spike protein instead of neutralizing antibody using different assays, such as chemiluminescent immunoassay, enzyme-linked immunosorbent assay, and 20 flow-cytometry analysis. The receptor binding domain is poorly conserved among SARS coronaviruses and relatively specific to SARS-CoV-2, whereas the antibody against the entire spike protein can be elevated after other coronavirus infections. 135, 136 However, the results from most of the assays were correlated with one another, 137 and also with neutralizing antibodies. 81, 138 Fourth, regarding the measurement method for the SARS-CoV-2-specific T cell response, several studies evaluated the response using SARS-CoV-2 spike peptides through IFN-γ production or AIM assay. 139 Whether these in vitro data can predict clinical outcomes of COVID-19 remains unknown, and some argue that these available evidences remain insufficient for clear guidance. 140 Additionally, all data used for our meta-analysis were from non-malignant patients, and there is only one study that evaluated the T cell response against patients with lymphoid malignancies to date. 39 This article revealed that T cell response was attenuated in myeloma patients compared with healthy controls, and also showed the discrepancy between T cell response and antibody formation capacity. In comparison with multiple sclerosis, 141 lymphoid malignancies cause a high disorder of lymphoid systems 9,10 ; thus, cellular response in these groups should be further analyzed. This meta-analysis demonstrated that lymphoid malignancies, as well as some subtypes, including CLL, NHL, and myeloma, attenuated humoral response. Treatment-naïve CLL and B-cell target therapy including anti-CD20 antibody, anti-CD38 therapy, and BTK inhibitor also demonstrated decreased humoral response. Regarding the interval from last anti-CD20 antibody therapy to the first vaccine dose, an interval < 6 months significantly attenuated seropositivity rates, and anti-CD20 antibody therapy > 12 months before vaccination still impaired humoral response. Cellular response was detected independent of anti-CD20 antibody therapy or antibody formation capacity. Further studies focusing on long-term follow-up and T cell responses in lymphoid malignancies are warranted. ・Patients with hematological malignancies are highly susceptible to severe COVID-19. ・mRNA vaccines have been widely used against COVID-19. ・Patients with lymphoid malignancies or those undergoing anti-CD20 antibody therapy experience an impaired humoral response. ・Cellular response can be detected independent of anti-CD20 antibody therapy in non-malignant patients.. Case fatality rate of cancer patients with COVID-19 in a New York Hospital system COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients Outcomes of COVID-19 in patients with CLL: a multicenter international experience COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus COVID-19 mRNA vaccines in hematologic malignancies patients Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised 34 patients and healthy controls in a prospective open-label clinical trial Poor neutralizing antibody responses in 132 patients with CLL, NHL and HL after vaccination against SARS-CoV-2: A prospective study Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma Serologic response to mRNA COVID-19 vaccination in lymphoma patients Seroconversion rates following COVID-19 vaccination among patients with cancer Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing with Humoral Response to 2 SARS-CoV-2 Vaccines in Patients with Multiple Sclerosis Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: Evidence for impaired humoral but inducible cellular immune response COVID-19 vaccine response in 36 people with multiple sclerosis Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccines B cell numbers predict humoral and cellular response upon SARS-CoV-2 vaccination among patients treated with rituximab Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Ocrelizumab Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2 Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccineinduced antibody and T cell immunity Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patients Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma SARS-CoV-2 vaccination in rituximab-treated patients: Evidence for impaired humoral but inducible cellular immune response Post-vaccination anti-SARS-CoV-2-antibody response in patients with multiple myeloma correlates with low CD19+ B-lymphocyte count and anti-CD38 treatment LB0002 COVID-19 Vaccine Safety in Patients With Rheumatic and Musculoskeletal Disease COVID symptoms, testing, shielding impact on patient reported outcomes and early vaccine responses in individuals with multiple myeloma Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy Serological responses after SARS-CoV-2 vaccination first dose in patients with lymphoid malignancy: first interim analysis of the UK PROSECO study Antibody Responses after SARS-CoV-2 Vaccination in Lymphoma Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patients Seroconversion rates following COVID-19 vaccination amongst patients with malignant disease-The impact of diagnosis and cancer-directed therapies Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti-neutrophil cytoplasmic antibody vasculitis Low rates of humoral response to BNT162b2 SARS-CoV-2 vaccination in patients with immune-mediated kidney diseases treated with rituximab Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: Evidence for impaired humoral but inducible cellular immune response Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab SARS-CoV-2 vaccination in rituximab-treated patients: Evidence for impaired humoral but inducible cellular immune response Correspondence on "SARS CoV-2 vaccination in rituximab-treated patients : evidence for impaired humoral but inducible cellular immune response Immunogenicity and safety 45 of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia Perturbation of the normal immune system in patients with CLL A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin"s Lymphoma Patients Treated with Rituximab-Containing Regimens Ibrutinib may 46 impair serological responses to influenza vaccination Effect of bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny Rituximab treatment results in impaired secondary humoral immune responsiveness BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients Preexisting and de novo humoral immunity to SARS-CoV-2 in humans Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting 49 total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals Covid-19 vaccination in patients with multiple myeloma: Focus on immune response Review of the COVID-19 Risk in Multiple Sclerosis